154 related articles for article (PubMed ID: 35921707)
21. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
22. Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis.
Liu X; Wang J; Li M; Qiu J; Li X; Qi L; Liu J; Liu P; Xie G; Wang X
J Gastroenterol Hepatol; 2023 Aug; 38(8):1438-1446. PubMed ID: 37415275
[TBL] [Abstract][Full Text] [Related]
23. Baicalein alleviates intrahepatic cholestasis by regulating bile acid metabolism via an FXR-dependent manner.
Huang W; Qian Y; Lin J; Wang F; Kong X; Tan W
Biochem Biophys Res Commun; 2024 Apr; 705():149670. PubMed ID: 38442444
[TBL] [Abstract][Full Text] [Related]
24. Role of farnesoid X receptor in cholestasis.
Yuan ZQ; Li KW
J Dig Dis; 2016 Aug; 17(8):501-509. PubMed ID: 27383832
[TBL] [Abstract][Full Text] [Related]
25. Farnesoid X receptor contributes to oleanolic acid-induced cholestatic liver injury in mice.
Feng H; Hu Y; Zhou S; Lu Y
J Appl Toxicol; 2022 Aug; 42(8):1323-1336. PubMed ID: 35128688
[TBL] [Abstract][Full Text] [Related]
26. Nuclear receptors as therapeutic targets in cholestatic liver diseases.
Zollner G; Trauner M
Br J Pharmacol; 2009 Jan; 156(1):7-27. PubMed ID: 19133988
[TBL] [Abstract][Full Text] [Related]
27. Arbutin Alleviates the Liver Injury of
Wu P; Qiao L; Yu H; Ming H; Liu C; Wu W; Li B
Front Cell Dev Biol; 2021; 9():758632. PubMed ID: 34926449
[TBL] [Abstract][Full Text] [Related]
28. Targeting FXR in cholestasis: hype or hope.
Fiorucci S; Distrutti E; Ricci P; Giuliano V; Donini A; Baldelli F
Expert Opin Ther Targets; 2014 Dec; 18(12):1449-59. PubMed ID: 25200104
[TBL] [Abstract][Full Text] [Related]
29. β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids
Klag T; Thomas M; Ehmann D; Courth L; Mailänder-Sanchez D; Weiss TS; Dayoub R; Abshagen K; Vollmar B; Thasler WE; Stange EF; Berg CP; Malek NP; Zanger UM; Wehkamp J
Front Immunol; 2018; 9():1735. PubMed ID: 30100908
[TBL] [Abstract][Full Text] [Related]
30. Protective effects of SRT1720 via the HNF1α/FXR signalling pathway and anti-inflammatory mechanisms in mice with estrogen-induced cholestatic liver injury.
Yu L; Liu X; Li X; Yuan Z; Yang H; Zhang L; Jiang Z
Toxicol Lett; 2016 Dec; 264():1-11. PubMed ID: 27818225
[TBL] [Abstract][Full Text] [Related]
31. Targeting FXR in Cholestasis.
Keitel V; Dröge C; Häussinger D
Handb Exp Pharmacol; 2019; 256():299-324. PubMed ID: 31201556
[TBL] [Abstract][Full Text] [Related]
32. Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid.
de Haan LR; Verheij J; van Golen RF; Horneffer-van der Sluis V; Lewis MR; Beuers UHW; van Gulik TM; Olde Damink SWM; Schaap FG; Heger M; Olthof PB
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33578971
[No Abstract] [Full Text] [Related]
33. Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR.
Kong L; Dong R; Huang K; Wang X; Wang D; Yue N; Wang C; Sun P; Gu J; Luo H; Liu K; Wu J; Sun H; Meng Q
Phytomedicine; 2021 Sep; 90():153629. PubMed ID: 34304130
[TBL] [Abstract][Full Text] [Related]
34. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice.
Wagner M; Fickert P; Zollner G; Fuchsbichler A; Silbert D; Tsybrovskyy O; Zatloukal K; Guo GL; Schuetz JD; Gonzalez FJ; Marschall HU; Denk H; Trauner M
Gastroenterology; 2003 Sep; 125(3):825-38. PubMed ID: 12949728
[TBL] [Abstract][Full Text] [Related]
35. Farnesoid X receptor: from medicinal chemistry to clinical applications.
Fiorucci S; Mencarelli A; Distrutti E; Zampella A
Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
[TBL] [Abstract][Full Text] [Related]
36. Farnesoid X receptor modulators (2011 - 2014): a patent review.
Sepe V; Distrutti E; Fiorucci S; Zampella A
Expert Opin Ther Pat; 2015; 25(8):885-96. PubMed ID: 26183029
[TBL] [Abstract][Full Text] [Related]
37. Sarmentol H derived from Sedum sarmentosum Bunge directly targets FXR to mitigate cholestasis by recruiting SRC-1.
Liu Z; Chen L; Chen M; Linghu L; Liao Z; Chen M; Wang G
Phytomedicine; 2024 Jul; 130():155759. PubMed ID: 38788394
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice.
Kim YC; Jung H; Seok S; Zhang Y; Ma J; Li T; Kemper B; Kemper JK
Hepatology; 2020 Jun; 71(6):2118-2134. PubMed ID: 31549733
[TBL] [Abstract][Full Text] [Related]
39. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
[TBL] [Abstract][Full Text] [Related]
40. Geniposide attenuates ANIT-induced cholestasis through regulation of transporters and enzymes involved in bile acids homeostasis in rats.
Wang L; Wu G; Wu F; Jiang N; Lin Y
J Ethnopharmacol; 2017 Jan; 196():178-185. PubMed ID: 27988401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
